Ascelia Pharma: Video presentation of the Q3 2025 Report
Today, we hosted an event with Deputy CEO Julie Waras Brogren from Ascelia Pharma. The presentation focused on the financial results and regulatory milestones achieved during the third quarter, with particular emphasis on the investment case for Orviglance. The event concluded with a Q&A session.
Watch the full presentation here: Event Video
Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a Digital IR/Corporate Visibility subscription agreement / MichaeL Friis, 13:45 06/11-2025
Sisäänkirjautuminen vaadittu
Tämä sisältö on näkyvissä vain sisäänkirjautuneille käyttäjille
Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital. Ascelia Pharma is listed on Nasdaq Small Cap Stockholm with ticker ACE.
Lue lisää yhtiösivulla
